Literature DB >> 12186504

The role of radiotherapy in the management of elevated calcitonin after surgery for medullary thyroid cancer.

N Fersht1, L Vini, R A'Hern, C Harmer.   

Abstract

Among 139 patients with medullary thyroid cancer (MTC) treated at the Royal Marsden Hospital between 1957-1998, 51 had persistently elevated calcitonin levels after initial surgery in the absence of clinically or radiologically demonstrable residual disease. Of these, 24 were treated with radiotherapy because of advanced local disease at presentation; this resulted in normalization of calcitonin in only 1 patient, although 10 remained free of clinical recurrence. Surveillance alone was used in the remaining 27 patients, of whom 8 (30%) remained free of overt disease. Local relapse rate was significantly lower after radiotherapy (29% vs. 59%) but there was no significant difference in 10-year survival between the two groups (72% vs. 60%). In view of this favorable long-term survival of patients with elevated calcitonin on observation, we cannot recommend the routine use of radiotherapy. However, it does appear to have a role in those presenting with more advanced disease to reduce the incidence of loco-regional relapse.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12186504     DOI: 10.1089/10507250152741019

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  9 in total

1.  Adjuvant external beam radiation for medullary thyroid carcinoma.

Authors:  Steve R Martinez; Shannon H Beal; Allen Chen; Steven L Chen; Philip D Schneider
Journal:  J Surg Oncol       Date:  2010-08-01       Impact factor: 3.454

2.  Aggressive medullary thyroid cancer, an analysis of the Irish National Cancer Registry.

Authors:  P Lennon; S Deady; N White; D Lambert; M L Healy; A Green; J Kinsella; C Timon; J P O' Neill
Journal:  Ir J Med Sci       Date:  2016-04-15       Impact factor: 1.568

Review 3.  Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.

Authors:  Samuel A Wells; Furio Pacini; Bruce G Robinson; Massimo Santoro
Journal:  J Clin Endocrinol Metab       Date:  2013-06-06       Impact factor: 5.958

4.  Outcomes of surgery and postoperative radiation therapy in managing medullary thyroid carcinoma.

Authors:  Andries H Groen; Thomas H Beckham; Thera P Links; Debra A Goldman; Eric J Sherman; Michael M Tuttle; Hendrik P Bijl; Richard J Wong; John Th M Plukker; Nancy Y Lee
Journal:  J Surg Oncol       Date:  2019-11-16       Impact factor: 3.454

5.  Vandetanib for the treatment of metastatic medullary thyroid cancer.

Authors:  Nils Degrauwe; Julie Ann Sosa; Sanziana Roman; Hari A Deshpande
Journal:  Clin Med Insights Oncol       Date:  2012-06-07

6.  A role for radiotherapy in the management of advanced medullary thyroid carcinoma: the mayo clinic experience.

Authors:  Jason A Call; Jonathan S Caudill; Bryan McIver; Robert L Foote
Journal:  Rare Tumors       Date:  2013-07-12

7.  Recurrent spinal metastasis of a sporadic medullary carcinoma of the thyroid after radiation therapy: a case report and review of the literature.

Authors:  Christopher Munoz-Bendix; Antonio Santacroce; Kristin Gierga; Frank W Floeth; Hans-Jakob Steiger; Marco Antonio Penalonzo; Sven Oliver Eicker
Journal:  Clin Case Rep       Date:  2015-11-09

8.  Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging.

Authors:  G Pellegriti; S Leboulleux; E Baudin; N Bellon; C Scollo; J P Travagli; M Schlumberger
Journal:  Br J Cancer       Date:  2003-05-19       Impact factor: 7.640

9.  Putative BRAF activating fusion in a medullary thyroid cancer.

Authors:  Katayoon Kasaian; Sam M Wiseman; Blair A Walker; Jacqueline E Schein; Martin Hirst; Richard A Moore; Andrew J Mungall; Marco A Marra; Steven J M Jones
Journal:  Cold Spring Harb Mol Case Stud       Date:  2016-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.